Home Companies Catalysts Deep Dives
Promacta eltrombopag APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaImmunology
Launch2008-11-20
US LOE2028-11-01
Peak Sales Est$2000M
Formulations[{"id":"promacta-oral","doses":"12.5mg, 25mg, 50mg, 75mg, 100mg tablets; oral suspension","route":"O
Companies
NVS (ORIGINATOR)100%
Mechanism: Thrombopoietin receptor agonist
Expert: Small molecule agonist of the thrombopoietin receptor, stimulating megakaryopoiesis
Everyday: Stimulates production of platelets
Targets: ["TPOR"]
Revenue History
PeriodRevenue ($M)
2024$1,150M
2025$1,180M
Programs (2)
IndicationStageKey StudyRegional Status
Chronic ITPAPPROVEDRAISE[{"stage":"APPROVED","region":"US","approval_date":"2008-11-20"},{"stage":"APPRO
Severe aplastic anemiaAPPROVEDRACE[{"stage":"APPROVED","region":"US","approval_date":"2014-08-25"}]
Notes
TPO agonist for ITP and aplastic anemia. Originally GSK.
Data from Supabase · Updated 2026-03-24